Gilead Sciences (GILD) Target Price Upped to $85 at Needham & Company Post Q3

October 30, 2013 12:26 PM EDT Send to a Friend
Get Alerts GILD Hot Sheet
Price: $106.09 -0.54%

Rating Summary:
    23 Buy, 5 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 29 | Down: 28 | New: 24
Trade GILD Now!
Join SI Premium – FREE
Needham & Company analyst Alan Carr, Ph.D. reiterated a Buy and raised his price target on Gilead Sciences (NASDAQ: GILD) from $70 to 85 following strong Q3 results and outlook.

Carr weighs in: "Total revenues were $2.78B, above our $2.64B and consensus $2.72B estimates. Annual product sales guidance was raised from $10.0-10.2B to $10.3-10.4B. Non-GAAP EPS of $0.52 exceeded our and consensus expectations for $0.48. Highly anticipated sofosbuvir FDA approval in HCV is expected by the 12/8/13 PDUFA date. We model strong revenue growth 2014+. Other key events in 4Q13 include Phase 3 sofosbuvir/ledipasvir ION trial data and Phase 2 sofosbuvir/GS-5816 data."

The firm raised FY 2013 EPS from $1.96 to $1.97 and FY 2014 EPS was trimmed from $2.76 to $2.57,

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $69.50 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Needham & Company

Add Your Comment